Sugi Predict

Sugi Predict / Compounds / SCHEMBL888989

SCHEMBL888989

SCHEMBL888989

COC(=O)N[C@H](C(=O)N1CCC[C@H]1CNC(=O)C(C)C)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 4/20 0.45
▸ DPP8 Q6V1X1 1/20 0.45
▸ DPP9 Q86TI2 1/20 0.45
▸ CYP3A4 P08684 7/20 0.45
▸ CYP2C9 P11712 5/20 0.45
▸ NR1I2 O75469 2/20 0.45
▸ ABCB11 O95342 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ PREP P48147 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ FAP Q12884 1/20 0.43
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2D6 P10635 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ELANE P08246 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL888937 0.96 CYP3A4 (0.42) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL888936 0.93 CYP3A4 (0.39) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL12771365 0.93 CYP3A4 (0.39) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL12824174 0.89 DPP4 (0.52) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL12824316 0.88 DPP4 (0.45) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL13062656 0.86 CYP3A4 (0.49) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL12755497 0.86 DPP4 (0.48) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL13014840 0.86 DPP4 (0.48) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL15976258 0.86 CYP3A4 (0.49) DPP4DPP8DPP9CYP3A4CYP2C9
SCHEMBL12824307 0.86 DPP4 (0.48) DPP4DPP8DPP9CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822700-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-09-02 — — US disclosed
US-8815928-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-08-26 — — US disclosed
US-8759332-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-06-24 — — US disclosed
US-8703938-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-04-22 — — US disclosed
US-20110070197-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-24 — — US disclosed
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 — — US disclosed
US-20110064696-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 — — US disclosed
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 DPP4 644/4885DPP8 906/4885DPP9 887/4885
US-20110064695-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 DPP4 644/4885DPP8 906/4885DPP9 887/4885
US-20110064696-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 DPP4 644/4885DPP8 906/4885DPP9 887/4885
US-20110070197-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 DPP4 644/4885DPP8 906/4885DPP9 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.